Portola Pharmaceuticals (NASDAQ:PTLA) Receives News Impact Score of 0.06
Media stories about Portola Pharmaceuticals (NASDAQ:PTLA) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.8399086720976 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Portola Pharmaceuticals Inc (PTLA) Forecasted to Earn FY2019 Earnings of $0.82 Per Share (americanbankingnews.com)
- Shares of PTLA Up 18.8% Since Uptrend Call on Shares (mysmartrend.com)
- Portola Pharmaceuticals Inc : Investor Network: Portola Pharmaceuticals, Inc. to Host Earnings Call (4-traders.com)
- These Biotech Stocks are BOOMING (finance.yahoo.com)
- Portola Pharmaceuticals: Updates To Thesis – Seeking Alpha (seekingalpha.com)
Portola Pharmaceuticals (NASDAQ PTLA) opened at 55.68 on Friday. The firm’s market cap is $3.21 billion. Portola Pharmaceuticals has a 52-week low of $15.68 and a 52-week high of $67.10. The firm’s 50-day moving average price is $60.73 and its 200 day moving average price is $42.42.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by $0.12. The business had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.28 million. Portola Pharmaceuticals had a negative return on equity of 145.12% and a negative net margin of 807.93%. The company’s quarterly revenue was down 10.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.02) EPS. On average, equities analysts anticipate that Portola Pharmaceuticals will post ($4.86) earnings per share for the current year.
Several brokerages recently issued reports on PTLA. Credit Suisse Group restated a “neutral” rating and issued a $58.00 price target (up previously from $39.00) on shares of Portola Pharmaceuticals in a research report on Monday, June 26th. Citigroup Inc. set a $51.00 price target on Portola Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, April 19th. ValuEngine upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $46.00 price target on Portola Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, May 9th. Finally, Morgan Stanley boosted their price target on Portola Pharmaceuticals from $50.00 to $70.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $63.77.
In other Portola Pharmaceuticals news, insider John T. Curnutte sold 10,000 shares of Portola Pharmaceuticals stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total value of $650,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder (Mauritius) Pte Ltd Maxwell sold 1,700,000 shares of Portola Pharmaceuticals stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $34.40, for a total transaction of $58,480,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,289,656 shares of company stock worth $91,298,131. 4.90% of the stock is currently owned by company insiders.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.